You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
Register for free to read this article
As a service to the community, this article is available for free. Existing users log in.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Abstract
The development and commercialization of diagnostic assays is distinct from that of therapeutic drugs in many important respects; for example, there are more variable regulatory requirements and reduced outside investments for diagnostics. The diagnostics industry has a pro-collaborative stance, because there is considerable mutual benefit in working in partnership with university or government researchers. However, there are substantial barriers to industry-academic collaborations. A Clinical and Translational Science Awards Industry Forum titled “Promoting Efficient and Effective Collaborations Among Academia, Government, and Industry” was held in February 2010, and a session at this forum was organized to list some of the most important barriers to diagnostics development and to discuss some possible solutions.
Footnotes
-
Citation: G. Evans, F. Austin, Collaborations Among Academia, Government, and Industry in the Diagnostics Space: Barriers and Some Ideas for Solutions. Sci. Transl. Med. 2, 63mr3 (2010).
- Copyright © 2010, American Association for the Advancement of Science